Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ALBT - Avalon GloboCare Corp.

3.4
0.100   2.941%

Share volume: 8,078
Last Updated: Tue 04 Feb 2025 10:00:00 PM CET

PREVIOUS CLOSE
CHG
CHG%
$3.30
0.06
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Historical prices Events Documents Notes Dividends
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.34%
1 Month
-13.04%
3 Months
-5.56%
6 Months
1,052.54%
1 Year
752.13%
2 Year
5.39%
Key data
Stock price
$3.40
P/E Ratio 
0.00
DAY RANGE
$3.23 - $3.40
EPS 
-$2.93
52 WEEK RANGE
$0.16 - $6.55
52 WEEK CHANGE
$792.39
MARKET CAP 
2.887 M
YIELD 
N/A
SHARES OUTSTANDING 
15.984 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
-0.30
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$8,710
AVERAGE 30 VOLUME 
$33,299
Company detail
CEO: David K. Jin
Region: US
Website: http://www.avalon-globocare.com/
Employees: 5
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

Avalon GloboCare Corp. owns and operates commercial real estate properties in the United States and the People's Republic of China. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia. It is also developing RNA-based FASH-CARTM cell therapy platform.

Recent news